BIIB today
$252.04-$1.36 (-0.54%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourLeaning Bearish
1 hourBearish
15 minLeaning Bullish
5 minConsolidating
Daily trend turns down below $231.04
Key levels
Resistance$268.30
Resistance$258.78
Support$240.00
Support$231.04
Latest news & SEC filings
AnalystPiper Sandler keeps Overweight on Biogen, lifts price target to $305
All BIIB news →About Biogen
Biogen is a biotechnology company that researches, develops, and markets medicines for neurological and rare conditions. Its portfolio spans therapies for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, ALS, postpartum depression, and Alzheimer's disease, several of which are developed with partners such as Eisai. It also pursues licensing and research collaborations in immunology and central nervous system disorders. The company serves healthcare providers and patients across North America, Europe, and Asia.
Based on the company's 10-K filed Feb 6, 2026.
Nasdaq · Healthcare
BIOGEN INC. (BIIB)
What Is the Price Target for BIIB?
SEPT Low Target
$225.00
SEPT Mid Target
$276.00
SEPT High Target
$310.00
Analyst Consensus
$276.00
Is BIIB a Buy or Sell Right Now?
Thesis
- •Revenue growing 2.2% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BIIB.
Start Free Trial →Is BIIB Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$259.45
30
Moat Score
NONE
5/9
Piotroski Score
3.5
Altman Z-Score
What Is Smart Money Doing with BIIB?
Insider Signal
NEUTRAL
1 buys / 1 sells (90d)
Congress Signal
BUYING
8 buys / 5 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Godbout Sean | officer | Buy | 27 | - | Oct 2, 2026 |
| Godbout Sean | officer | Sale | 8 | $2K | Oct 2, 2026 |
| HAWKINS WILLIAM A | director | Buy | 1,505 | - | Jun 9, 2026 |
| SHERWIN STEPHEN A | director | Buy | 1,505 | - | Jun 9, 2026 |
| Rowinsky Eric K | director | Buy | 1,505 | - | Jun 9, 2026 |
| Mantas Jesus B | director | Buy | 1,505 | - | Jun 9, 2026 |
| LANGER SUSAN | director | Buy | 1,505 | - | Jun 9, 2026 |
| Patolawala Monish D | director | Buy | 1,505 | - | Jun 9, 2026 |
| Pangalos Menelas N | director | Buy | 2,370 | - | Jun 9, 2026 |
| Pangalos Menelas N | director | Buy | 1,505 | - | Jun 9, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BIIB Growth Story
Revenue YoY
2.2%
3yr Revenue CAGR
-0.9%
EPS Growth YoY
-21.38%
FCF Growth YoY
-24.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for BIIB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BIIB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:30:28 | $252.04 | 1,645 | $$415K | SELL |
| 20:30:28 | $252.00 | 1,854 | $$467K | SELL |
| 20:17:45 | $251.92 | 3,453 | $$870K | MIDPOINT |
| 20:16:12 | $251.91 | 6,719 | $$1.7M | MIDPOINT |
| 19:10:44 | $251.99 | 15,330 | $$3.9M | SELL |
5 dark pool trades shown · $$7.3M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for BIIB
PREVIEWSEPT Investing provides real-time options flow tracking for BIIB, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $205 | Dec 18 | 36 | $$180 | 1 | SWEEP |
| PUT | $215 | Dec 18 | 36 | $$300 | 1 | SWEEP |
| PUT | $230 | Jun 17 | 217 | $$1930 | 1 | SWEEP |
| PUT | $230 | Jun 17 | 217 | $$1930 | 1 | SWEEP |
| CALL | $270 | Jun 17 | 217 | $$2870 | 1 | SWEEP |
5 options trades shown · 20% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About BIIB
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for BIIB. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup — $BIIB (BIOGEN INC.) Price: $214.58 | Zone: $199.40 — $218.59 Conviction: HIGH | Analyst upside: +6.5% Near resistance (79% of range) — breakout watch. Strong positive news (14+ vs 1-)
Join 3,500+ traders discussing BIIB in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BIOGEN INC. (BIIB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BIIB — frequently asked questions
What is BIIB stock price today?
BIOGEN INC. (BIIB) is at $252.04, down 0.54% (-$1.36) at the Nov 12, 2026 close.
Why is BIIB stock moving today?
Latest BIIB news — Nov 9, 2026: Piper Sandler keeps Overweight on Biogen, lifts price target to $305
Why did BIIB stock move on Oct 12, 2026?
Biogen shares closed at $229.41, down 1.95% on the day, despite a notable analyst upgrade. JP Morgan raised its rating on the stock from Neutral to Overweight and increased its price target from $210 to $300, a bullish signal that may not have been fully reflected in today's trading.
What is the BIIB price target?
The average analyst price target for BIIB is $276.00, ranging from $225 to $310, based on 18 analysts.
What do analysts rate BIIB?
Analyst ratings for BIIB: 25 Buy, 10 Hold, 1 Sell — consensus Buy.
Did BIIB beat earnings?
BIIB last reported on Oct 28, 2026: EPS $2.62 vs $1.99 expected — a beat of 31.7%.
What is BIIB's P/E ratio?
BIIB trades at a P/E of 107.0 vs a Healthcare average of 16.8.
Does BIIB pay a dividend?
BIIB does not currently pay a dividend.
What are BIIB support and resistance levels?
Support: $240.00, $231.04, $218.00. Resistance: $258.78, $268.30, $278.95.
What are insiders doing with BIIB?
Insider activity: NEUTRAL, 1 buys and 1 sells in the last 90 days.
What is the latest news on BIIB?
Nov 9, 2026: Piper Sandler keeps Overweight on Biogen, lifts price target to $305